Compound Planning Inc. Has $2.53 Million Position in AstraZeneca PLC $AZN

Compound Planning Inc. grew its position in AstraZeneca PLC (NASDAQ:AZN) by 37.7% during the 3rd quarter, HoldingsChannel reports. The firm owned 32,928 shares of the company’s stock after purchasing an additional 9,014 shares during the quarter. Compound Planning Inc.’s holdings in AstraZeneca were worth $2,526,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Cary Street Partners Investment Advisory LLC lifted its holdings in AstraZeneca by 27.8% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 4,002 shares of the company’s stock worth $307,000 after acquiring an additional 871 shares in the last quarter. Legacy Financial Advisors Inc. acquired a new stake in shares of AstraZeneca during the third quarter worth about $1,059,000. Transatlantique Private Wealth LLC acquired a new stake in shares of AstraZeneca during the third quarter worth about $3,637,000. Sound View Wealth Advisors Group LLC lifted its holdings in shares of AstraZeneca by 2.8% during the 3rd quarter. Sound View Wealth Advisors Group LLC now owns 46,791 shares of the company’s stock valued at $3,590,000 after purchasing an additional 1,257 shares in the last quarter. Finally, Clearstead Advisors LLC grew its position in shares of AstraZeneca by 6.2% in the 3rd quarter. Clearstead Advisors LLC now owns 10,120 shares of the company’s stock valued at $776,000 after purchasing an additional 591 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Trading Up 0.9%

AstraZeneca stock opened at $206.77 on Wednesday. The company has a market cap of $320.68 billion, a price-to-earnings ratio of 68.69, a P/E/G ratio of 1.59 and a beta of 0.34. The firm has a 50-day moving average of $128.98 and a 200-day moving average of $99.61. The company has a debt-to-equity ratio of 0.54, a current ratio of 0.88 and a quick ratio of 0.69. AstraZeneca PLC has a one year low of $122.48 and a one year high of $212.71.

AstraZeneca Dividend Announcement

The business also recently declared a dividend, which will be paid on Monday, March 23rd. Shareholders of record on Friday, February 20th will be given a dividend of $1.595 per share. The ex-dividend date of this dividend is Friday, February 20th. This represents a dividend yield of 156.0%. AstraZeneca’s payout ratio is 74.83%.

Analyst Upgrades and Downgrades

Several analysts have commented on AZN shares. Barclays restated an “overweight” rating on shares of AstraZeneca in a report on Tuesday, January 6th. TD Cowen reaffirmed a “buy” rating on shares of AstraZeneca in a research report on Tuesday, December 9th. Morgan Stanley reiterated an “overweight” rating and set a $103.00 target price on shares of AstraZeneca in a report on Wednesday, December 3rd. Wall Street Zen lowered AstraZeneca from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 17th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of AstraZeneca in a report on Wednesday, January 21st. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, AstraZeneca currently has an average rating of “Moderate Buy” and a consensus price target of $95.75.

AstraZeneca Company Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.